【中金升亚盛医药(06855.HK)目标价至69港元APG-2575数据亮眼】金十数据6月11日讯，中金发表研究报告指，亚盛医药(06855.HK)近日在美国临床肿瘤学会年会上口头报告了Bcl-2抑制剂APG-2575(lisaftoclax)合并阿扎胞苷针对髓系恶性肿瘤的Ib/II期研究数据，并更新了MDM2-p53抑制剂APG-115(alrizomadlin)治疗晚期腺样囊性癌或其它实体瘤患者的II期临床研究资料。该行认为，APG-2575R/RAML数据亮眼，展现出克服维奈克拉抗药性的潜力。鉴于维奈克拉尚未核准1LMDS，此适应症竞争格局良好，建议关注临床开展情况。该行基本维持集团今明两年的净亏损预测，分别为10.95亿及3.19亿元人民币，维持跑赢行业评级，目标价上调25.5%至69港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.